Aquestive Refiles FDA Application for Anaphylm Film

Aquestive Therapeutics said it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm, a sublingual film for Type I allergic reactions including anaphylaxis, with the filing supported by positive topline results; AQST last traded at 4.82, up 0.21%, as of 20:00 GMT on Sept. 16, 2026.

Aquestive Therapeutics (AQST) has put its lead product back in front of U.S. regulators. The company said it resubmitted its New Drug Application to the Food and Drug Administration for Anaphylm, a sublingual film intended to treat Type I allergic reactions, including anaphylaxis. The filing, according to the company, is supported by positive topline results.

The resubmission matters more than the average regulatory housekeeping item, because Anaphylm is not an incremental reformulation of an existing pill. It is a film placed under the tongue, aimed at a category of emergency medicine that has been delivered by injection for decades. If cleared, it would give patients and caregivers a route to epinephrine that involves no needle, no autoinjector mechanism and no refrigerated storage discipline built around a spring-loaded device.

What a sublingual film changes about emergency dosing

Type I allergic reactions are the immediate, IgE-mediated responses most people know from food, insect sting and drug allergies. At the severe end sits anaphylaxis, where the reaction becomes systemic and minutes matter. The standard of care is prompt epinephrine, and the practical problem in the real world has never been the drug itself — it is whether the patient has the device on hand and is willing and able to use it.

That is the gap a film is designed to close. A small dosage form that sits in a wallet or pocket removes several of the reasons injections go unused: fear of needles, reluctance by a bystander to administer one, and the bulk of carrying a device at all times. Aquestive's pitch has consistently been about adherence and carriage rather than about beating injection on pharmacology.

None of that is settled by a resubmission. A refiling restarts the FDA's clock; it does not tell the market what the agency thought the first time or what it will conclude now. The company has said only that positive topline results underpin the new application.

How the shares are positioned going in

AQST closed at 4.82, up 0.21% on the day, with a session range of 4.74 to 4.95 against a prior close of 4.81, as of the last trade at 20:00 GMT on Sept. 16, 2026. That is a quiet tape for a company whose entire valuation case rests on a single regulatory outcome — a sign the market was not repricing the name ahead of the announcement rather than evidence of indifference to it.

The broader backdrop was mixed on the same session. The S&P 500, via SPY, ended at $754.05, down 0.44%, and the Dow 30 tracker DIA closed at $515.22, off 1.15%. The Nasdaq 100 proxy QQQ was essentially flat at $704.72, up 0.03%. Small-cap, single-asset biotech tends to trade on its own news regardless, and that is the structure here: the file-and-wait period is the stock's dominant variable.

Details of the resubmission were reported by Nasdaq Markets.

Why the second pass is a different kind of risk

Resubmissions are a distinct phase of the drug approval process and they carry a distinct risk profile. On a first-cycle review, the open questions are broad: does the dataset support the label, is the manufacturing package adequate, is the clinical package complete. On a resubmission, the questions are usually narrower and better defined, because the sponsor has been told where the deficiency sat. That tends to compress the range of outcomes — but it does not eliminate the possibility that the agency remains unsatisfied.

For investors, the practical consequence is that the information content of the next FDA communication is high. A single-product company that refiles has, in effect, told the market it believes it has addressed what was asked of it. Confirmation or rejection of that belief moves the equity far more than any interim disclosure would.

What has not been stated publicly in the company's announcement, and therefore should not be assumed: the specific review timeline the FDA assigns to the resubmission, the classification of the filing, or any commercial forecast for the product. Those are the details that will fill in over the coming weeks as the agency acknowledges the submission.

The commercial logic behind needle-free epinephrine

The strategic case for Anaphylm is straightforward even without a number attached to it. Epinephrine for acute allergic reactions is a rescue category — patients are prescribed it, carry it, and in most cases never fire it. That dynamic makes convenience and form factor unusually important commercial levers, because the purchase decision is driven by preparedness rather than by symptom relief in the moment of prescribing.

A film format also changes the distribution and stocking conversation. Schools, restaurants, camps and workplaces that keep emergency epinephrine on site currently manage devices with expiry dates and handling requirements. A flat, non-mechanical dosage form is a simpler inventory item, which is a quieter but real part of the addressable opportunity.

The counterweight is entrenchment. Injectable epinephrine is the default in treatment guidelines, in prescriber habit and in caregiver training. Displacing a standard of care takes more than a novel format; it takes labeling that clinicians trust and, typically, years of prescriber education. That is a post-approval problem, but it is the one that determines whether a clearance becomes revenue.

What to watch from here

• FDA acknowledgment of the resubmission and any review classification the agency assigns, which sets the calendar the stock will trade around.
• Fuller disclosure of the topline results cited as support for the filing, including how the data address whatever the agency previously flagged.
• Any company commentary on commercial readiness — manufacturing scale, sales infrastructure and payer discussions — which signals how quickly an approval could translate into shipments.
• Balance sheet and financing steps, since a single-product developer approaching a potential launch usually needs to fund it.

For now the position is simple to describe and hard to handicap. The application is in, the company says the data support it, and the shares closed the most recent session barely changed at 4.82. The next meaningful datapoint comes from the regulator, not the company.

Key facts

• AQST last price: 4.82, +0.21%, as of 20:00 GMT Sept. 16, 2026
• Regulatory action: New Drug Application resubmitted to the FDA
• Product: Anaphylm sublingual film
• Indication: Type I allergic reactions, including anaphylaxis

Frequently asked questions

What did Aquestive Therapeutics announce?

Aquestive Therapeutics said it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm, a sublingual film for the treatment of Type I allergic reactions, including anaphylaxis. The company stated the resubmission is supported by positive topline results. No review timeline was disclosed in the announcement.

What is Anaphylm?

Anaphylm is a sublingual film — a thin dosage form placed under the tongue — developed to treat Type I allergic reactions, including anaphylaxis. Unlike conventional emergency epinephrine, it does not involve an injection or an autoinjector device, which is the basis of the company's case around patient carriage and willingness to use it.

What are Type I allergic reactions?

Type I allergic reactions are immediate, IgE-mediated immune responses, commonly triggered by foods, insect stings or drugs. At the severe end is anaphylaxis, a systemic reaction that can be life-threatening within minutes. Prompt administration of epinephrine is the accepted first-line treatment for severe cases.

Where did AQST shares last trade?

AQST closed at 4.82, up 0.21%, with a session range of 4.74 to 4.95 against a prior close of 4.81, as of the last trade at 20:00 GMT on Sept. 16, 2026. The market was closed at the time of writing, so that figure represents the most recent traded price rather than a live quote.

Does a resubmission mean the drug will be approved?

No. Resubmitting a New Drug Application restarts the FDA's review process; it does not guarantee a favorable outcome. A resubmission typically addresses deficiencies the agency identified previously, which can narrow the range of open questions, but the regulator can still decline to approve the application.

Why is needle-free epinephrine considered commercially attractive?

Emergency epinephrine is a rescue product that patients carry but rarely use, so convenience and form factor strongly influence whether it is carried at all. A film requires no needle or mechanical device, which the company argues improves carriage and willingness to administer, and simplifies stocking for schools, restaurants and workplaces.

Sources

• Aquestive Therapeutics Resubmits NDA For Anaphylm Sublingual Film — Nasdaq Markets

Photo: https://kaboompics.com/ · Pexels Licence — source